Reply To: CAR-T Referral Management

  • Mary Lynn Rae

    Member
    October 26, 2017 at 9:08 am

    We have only done one patient and it was an internal patient.  The ONC team managed the chemo and labs prior to the collection and then the SCT team took over from there…..

     

    Mary Lynn Rae, RN, MSN, CPHON

    Clinical Educator Hem/Onc/SCT & VAT

    Ann & Robert H. Lurie Children’s Hospital of Chicago

    T 312.227.4224 | mlrae@luriechildrens.org | luriechildrens.org

    225 East Chicago Avenue, Box 248, Chicago, Illinois 60611-2991

    image002.png@01CEAFCE.66E28C90image003.png@01CEAFCE.66E28C90 image005.png@01CEAFCE.66E28C90 image006.png@01CEAFCE.66E28C90 image007.png@01CEAFCE.66E28C90

     

     

    DesignTemplate2

    This message contains confidential information and is intended only for the individual named. If you are not the named addressee you should not disseminate, distribute or copy this e-mail. Please notify the sender immediately by e-mail if you have received this e-mail by mistake and delete this e-mail from your system. E-mail transmission cannot be guaranteed to be secure or error-free as information could be intercepted, corrupted, lost, destroyed, arrive late or incomplete, or contain viruses. The sender therefore does not accept liability for any errors or omissions in the contents of this message, which arise as a result of e-mail transmission. If verification is required please request a hard-copy version.  (LCHOC VER 1.0)

    ——Original Message——

    ​​Hi,
    Hoping for any experience you all have to share with regard to CAR-T referrals from other institutions. My questions are as follows:

    1. When you receive a referral for CAR-T therapy, who manages the chemotherapy and labs prior to collection? Do you always allow the referring institution to manage that chemo, knowing that as the patient is recovering, you have to get them in the small window they may have between ALC recovery and blasting off?
      1. If you do allow them to manage, at what point do you take over lab monitoring, so you are sure to hit the collection window?
    2. For bridging chemotherapy, while cells are being manufactured, do you always allow the referring institution to manage that treatment, with input from your team?
    3. Any other details you have to share would be much appreciated!

    Michelle

    ——————————
    Michelle Gillard, MSN, RN, CPHON
    Cellular Therapy Program Coordinator
    Phoenix Children’s Hospital
    Phoenix, AZ
    mgillard@phoenixchildrens.com
    ——————————